View Exam | PowerPak

1. According to current estimates, __________ of patients with diabetes have DR.

A. One-fourth B. One-third C. One-half D. Three-fourths

2. For which ocular complication of diabetes is anti-VEGF effective treatment?

A. Cataract B. DME C. DR D. DME and DR

3. Considering results from the Diabetic Retinopathy Clinical Research Network Protocol T study that compared aflibercept, bevacizumab, and ranibizumab for the treatment of DME, which anti-VEGF agent would be expected to provide the best improvement in vision in a patient whose presenting VA is 20/40?

A. Aflibercept B. Bevacizumab C. Ranibizumab D. No agent is preferred

4. A patient presents with DR without DME, and the decision is made to treat with an anti-VEGF agent to prevent progression of the DR to a vision-threatening form. Which anti-VEGF agent(s) are US Food and Drug Administration approved for treating DR?

A. Aflibercept and bevacizumab B. Aflibercept and ranibizumab C. Bevacizumab and ranibizumab D. None have a US Food and Drug Administration–approved indication for treatment of DR

5. Considering results from Protocol T that compared aflibercept, bevacizumab, and ranibizumab for the treatment of DME, which anti-VEGF agent would be expected to provide the best improvement in vision in a patient whose presenting VA is 20/60 at baseline after the first year of treatment?

A. Aflibercept B. Bevacizumab C. Ranibizumab D. No agent is preferred

6. Retina specialists have several concerns about step therapy requiring the use of bevacizumab for the initial treatment of DME. These concerns include all the following, EXCEPT:

A. Contamination risk B. Dose inaccuracy C. Less chance of vision improvement in certain clinical situations D. Risk for visually symptomatic bevacizumab particles

7. A study investigating prefilled ranibizumab syringes found that use of this technology reduced the rate of ________________________________.

A. Culture-positive endophthalmitis B. Dosing errors C. Noninfectious uveitis D. Silicone oil droplets in the vitreous

8. In the 2019 ASRS Preferences and Trends Survey, ___ of US respondents said they would choose bevacizumab for treating new-onset wet AMD if all anti-VEGF agents cost the same.

A. 8% B. 13% C. 52% D. 78%

9. All the following statements about DME are true, EXCEPT:

A. It is the most common cause of vision loss for patients with DR B. It results in blurring of central vision C. It develops only when DR advances to its proliferative stage D. The treatment of choice for DME is anti-VEGF therapy

10. The cost of providing anti-VEGF therapy to treat diabetic eye disease is expected to rise in the future because:

A. The number of people with diabetes is increasing B. Tachyphylaxis and tolerance to treatment are common problems, and they mandate more frequent injections C. The number of people with DR is expected to increase because of a trend toward poorer glycemic control in the population of patients with diabetes D. All the above

11. Considering the subgroup of eyes with severe DR at entry into Protocol T, the percentage that benefited with improvement in DR severity after 2 years was ___________________________.

A. Similar in the aflibercept, bevacizumab, and ranibizumab groups B. Significantly greater in both the aflibercept and ranibizumab groups than in the bevacizumab group C. Significantly greater in the aflibercept group than in both the bevacizumab and ranibizumab groups D. Significantly greater in the aflibercept group than in the bevacizumab group

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to current estimates, __________ of patients with diabetes have DR.

2. For which ocular complication of diabetes is anti-VEGF effective treatment?

4. A patient presents with DR without DME, and the decision is made to treat with an anti-VEGF agent to prevent progression of the DR to a vision-threatening form. Which anti-VEGF agent(s) are US Food and Drug Administration approved for treating DR?

5. Considering results from Protocol T that compared aflibercept, bevacizumab, and ranibizumab for the treatment of DME, which anti-VEGF agent would be expected to provide the best improvement in vision in a patient whose presenting VA is 20/60 at baseline after the first year of treatment?

6. Retina specialists have several concerns about step therapy requiring the use of bevacizumab for the initial treatment of DME. These concerns include all the following, EXCEPT:

7. A study investigating prefilled ranibizumab syringes found that use of this technology reduced the rate of ________________________________.

8. In the 2019 ASRS Preferences and Trends Survey, ___ of US respondents said they would choose bevacizumab for treating new-onset wet AMD if all anti-VEGF agents cost the same.

9. All the following statements about DME are true, EXCEPT:

10. The cost of providing anti-VEGF therapy to treat diabetic eye disease is expected to rise in the future because:

11. Considering the subgroup of eyes with severe DR at entry into Protocol T, the percentage that benefited with improvement in DR severity after 2 years was ___________________________.

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to current estimates, __________ of patients with diabetes have DR.

2. For which ocular complication of diabetes is anti-VEGF effective treatment?

4. A patient presents with DR without DME, and the decision is made to treat with an anti-VEGF agent to prevent progression of the DR to a vision-threatening form. Which anti-VEGF agent(s) are US Food and Drug Administration approved for treating DR?

5. Considering results from Protocol T that compared aflibercept, bevacizumab, and ranibizumab for the treatment of DME, which anti-VEGF agent would be expected to provide the best improvement in vision in a patient whose presenting VA is 20/60 at baseline after the first year of treatment?

6. Retina specialists have several concerns about step therapy requiring the use of bevacizumab for the initial treatment of DME. These concerns include all the following, EXCEPT:

7. A study investigating prefilled ranibizumab syringes found that use of this technology reduced the rate of ________________________________.

8. In the 2019 ASRS Preferences and Trends Survey, ___ of US respondents said they would choose bevacizumab for treating new-onset wet AMD if all anti-VEGF agents cost the same.

9. All the following statements about DME are true, EXCEPT:

10. The cost of providing anti-VEGF therapy to treat diabetic eye disease is expected to rise in the future because:

11. Considering the subgroup of eyes with severe DR at entry into Protocol T, the percentage that benefited with improvement in DR severity after 2 years was ___________________________.

« Return to Activity

Customers who Purchased
this Activity also Purchased